QQQ   258.54 (-2.06%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
QQQ   258.54 (-2.06%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
QQQ   258.54 (-2.06%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
QQQ   258.54 (-2.06%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
ACB   12.08 (+0.50%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
Log in

NASDAQ:ONCSOncoSec Medical Stock Price, Forecast & News

$2.78
+0.83 (+42.56 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.04
Now: $2.78
$2.85
50-Day Range
$1.96
MA: $2.15
$2.49
52-Week Range
$1.04
Now: $2.78
$2.97
Volume2.89 million shs
Average Volume249,631 shs
Market Capitalization$64.03 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (PISCES/KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (OMS-141/KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company has completed Phase I neoadjuvant clinical trial of ImmunoPulse IL-12 in combination with an anti-PD-1 in surgically resectable melanoma. Additionally, it is developing new DNA-encoded therapeutic candidates and tumor indications. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the PISCES/KEYNOTE-695 and OMS-141/KEYNOTE-890 studies; a collaboration with the GOG Foundation, Inc. to conduct a registration-enabled study of tavokinogene telseplasmid in women with recurrent/persistent cervical cancer; and a collaborative research agreement with Duke University School of Medicine in HER2+ breast cancer. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Read More
OncoSec Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.28 per share

Profitability

Net Income$-30,280,000.00

Miscellaneous

Employees33
Market Cap$64.03 million
Next Earnings Date9/21/2020 (Estimated)
OptionableNot Optionable

Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter.

OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

How has OncoSec Medical's stock been impacted by COVID-19 (Coronavirus)?

OncoSec Medical's stock was trading at $1.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ONCS shares have increased by 102.9% and is now trading at $2.78. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of OncoSec Medical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OncoSec Medical.

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release its next quarterly earnings announcement on Monday, September 21st 2020. View our earnings forecast for OncoSec Medical.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Inc (NASDAQ:ONCS) announced its earnings results on Monday, June, 15th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.01. View OncoSec Medical's earnings history.

When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?

OncoSec Medical's stock reverse split on the morning of Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ONCS?

1 brokerages have issued 12-month price targets for OncoSec Medical's shares. Their forecasts range from $6.00 to $6.00. On average, they expect OncoSec Medical's share price to reach $6.00 in the next year. This suggests a possible upside of 115.8% from the stock's current price. View analysts' price targets for OncoSec Medical.

Has OncoSec Medical been receiving favorable news coverage?

Press coverage about ONCS stock has trended very negative on Monday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OncoSec Medical earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about OncoSec Medical.

Are investors shorting OncoSec Medical?

OncoSec Medical saw a drop in short interest in June. As of June 15th, there was short interest totaling 140,400 shares, a drop of 21.9% from the May 31st total of 179,800 shares. Based on an average daily trading volume, of 335,400 shares, the short-interest ratio is currently 0.4 days. Approximately 1.6% of the shares of the company are short sold. View OncoSec Medical's Current Options Chain.

Who are some of OncoSec Medical's key competitors?

What other stocks do shareholders of OncoSec Medical own?

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the following people:
  • Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
  • Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 55)
  • Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 39)
  • Ms. Sara M. Bonstein, CFO, COO & Company Sec. (Age 38)
  • Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $2.78.

How big of a company is OncoSec Medical?

OncoSec Medical has a market capitalization of $64.03 million. OncoSec Medical employs 33 workers across the globe.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is www.oncosec.com.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.